86 related articles for article (PubMed ID: 3965689)
1. Clinical pharmacology of tomoxetine, a potential antidepressant.
Zerbe RL; Rowe H; Enas GG; Wong D; Farid N; Lemberger L
J Pharmacol Exp Ther; 1985 Jan; 232(1):139-43. PubMed ID: 3965689
[TBL] [Abstract][Full Text] [Related]
2. Norepinephrine uptake sites in the locus coeruleus of rat lines selectively bred for high and low alcohol preference: a quantitative autoradiographic binding study using [3H]-tomoxetine.
Hwang BH; Wang GM; Wong DT; Lumeng L; Li TK
Alcohol Clin Exp Res; 2000 May; 24(5):588-94. PubMed ID: 10832899
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action.
Lenke D; Gries J; Kretzschmar R
Arzneimittelforschung; 1981; 31(9a):1558-65. PubMed ID: 7197970
[TBL] [Abstract][Full Text] [Related]
4. The effect of nisoxetine (Lilly compound 94939), a potential antidepressant, on biogenic amine uptake in man.
Lemberger L; Terman S; Rowe H; Billings R
Br J Clin Pharmacol; 1976 Apr; 3(2):215-20. PubMed ID: 788744
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic effects in man of a specific serotonin-reuptake inhibitor.
Lemberger L; Rowe H; Carmichael R; Oldham S; Horng JS; Bymaster FP; Wong DT
Science; 1978 Jan; 199(4327):436-7. PubMed ID: 619465
[TBL] [Abstract][Full Text] [Related]
6. Fluoxetine: clinical pharmacology and physiologic disposition.
Lemberger L; Bergstrom RF; Wolen RL; Farid NA; Enas GG; Aronoff GR
J Clin Psychiatry; 1985 Mar; 46(3 Pt 2):14-9. PubMed ID: 3871765
[TBL] [Abstract][Full Text] [Related]
7. Evidence of the dual mechanisms of action of venlafaxine.
Harvey AT; Rudolph RL; Preskorn SH
Arch Gen Psychiatry; 2000 May; 57(5):503-9. PubMed ID: 10807491
[TBL] [Abstract][Full Text] [Related]
8. Antagonism by tomoxetine of the depletion of norepinephrine and epinephrine in rat brain by alpha-methyl-m-tyrosine.
Fuller RW; Hemrick-Luecke SK
Res Commun Chem Pathol Pharmacol; 1983 Jul; 41(1):169-72. PubMed ID: 6604933
[TBL] [Abstract][Full Text] [Related]
9. Tomoxetine (Eli Lilly & Co).
Preti A
Curr Opin Investig Drugs; 2002 Feb; 3(2):272-7. PubMed ID: 12020059
[TBL] [Abstract][Full Text] [Related]
10. Tyramine pharmacodynamics during combined administration of lazabemide and moclobemide.
Dingemanse J; Hussain Y; Korn A
Int J Clin Pharmacol Ther; 1996 Apr; 34(4):172-7. PubMed ID: 8861736
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacological actions of (+/-)-(1'R*,3R*)-3-phenyl-1- [1',2',3',4'-tetrahydro-5',6'-methylene-dioxy-1'-naphthalenyl) methyl] pyrrolidine methanesulfonate (ABT-200), a potential antidepressant agent that antagonizes alpha-2 adrenergic receptors and inhibits the neuronal uptake of norepinephrine.
Hancock AA; Buckner SA; Giardina WJ; Brune ME; Lee JY; Morse PA; Oheim KW; Stanisic DS; Warner RB; Kerkman DJ
J Pharmacol Exp Ther; 1995 Mar; 272(3):1160-9. PubMed ID: 7891328
[TBL] [Abstract][Full Text] [Related]
12. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects.
Azzaro AJ; Vandenberg CM; Blob LF; Kemper EM; Sharoky M; Oren DA; Campbell BJ
J Clin Pharmacol; 2006 Aug; 46(8):933-44. PubMed ID: 16855078
[TBL] [Abstract][Full Text] [Related]
13. Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects.
Farid NA; Bergstrom RF; Ziege EA; Parli CJ; Lemberger L
J Clin Pharmacol; 1985; 25(4):296-301. PubMed ID: 4008676
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of lortalamine, a new potent non-tricyclic antidepressant.
Depin JC; Betbeder-Matibet A; Bonhomme Y; Muller AJ; Berthelon JJ
Arzneimittelforschung; 1985; 35(11):1655-62. PubMed ID: 4091869
[TBL] [Abstract][Full Text] [Related]
15. Safety and pharmacologic activity of a new nitrate ester, ITF 296, after intravenous administration in healthy volunteers.
Sardina M; Love R; Mizrahi J; Monzani V; Bianchini C
J Cardiovasc Pharmacol; 1995; 26 Suppl 4():S72-9. PubMed ID: 8839230
[TBL] [Abstract][Full Text] [Related]
16. Fluoxetine, a selective serotonin uptake inhibitor.
Lemberger L; Rowe H; Carmichael R; Crabtree R; Horng JS; Bymaster F; Wong D
Clin Pharmacol Ther; 1978 Apr; 23(4):421-9. PubMed ID: 630789
[No Abstract] [Full Text] [Related]
17. Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050.
Shaw AM; Boules M; Zhang Y; Williams K; Robinson J; Carlier PR; Richelson E
Eur J Pharmacol; 2007 Jan; 555(1):30-6. PubMed ID: 17109850
[TBL] [Abstract][Full Text] [Related]
18. On the mechanism of antidepressant-like action of berberine chloride.
Kulkarni SK; Dhir A
Eur J Pharmacol; 2008 Jul; 589(1-3):163-72. PubMed ID: 18585703
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and safety of deramciclane during multiple oral dosing.
Kanerva H; Kilkku O; Helminen A; Rouru J; Scheinin M; Huupponen R; Klebovich I; Drabant S; Urtti A
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):589-97. PubMed ID: 10599951
[TBL] [Abstract][Full Text] [Related]
20. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
